** Shares of drugmaker Bristol Myers Squibb BMY.N fall 1.6% to $50.50 in extended trading
** Co says its experimental heart disease drug, mavacamten, did not meet the main goals in a late-stage study
** The drug was being tested to treat adult patients with with the so-called non-obstructive form of hypertrophic cardiomyopathy (nHCM), an inherited condition characterized by thickening of heart muscles
** The drug, branded as Camzyos, did not improve symptoms or exercise more easily in patients with nHCM
** The drug is already approved in the U.S. for the obstructive form of the disease
** As of last close, stock down 9.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.